Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances

被引：0

作者：

Thalambedu, Nishanth ^{[1
]}

Lal, Bhavesh Mohan ^{[1
]}

Harbaugh, Brent ^{[2
]}

Alapat, Daisy V. ^{[2
]}

Gaddam, Mamatha ^{[3
]}

Sanchez, Cesar Giancarlo Gentille ^{[3
]}

Kumaran, Muthu ^{[1
]}

Varma, Ankur ^{[3
]}

机构：

[1] Univ Arkansas Med Sci, Dept Hematol & Oncol, Little Rock, AR 72205 USA

[2] Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA

[3] Univ Arkansas Med Sci, Winthrop P Rockefeller Canc Inst, 4301 W Markham St,Slot 508, Little Rock, AR 72205 USA

来源：

CANCERS | 2025年 / 17卷 / 03期

关键词：

myelodysplastic syndrome; acute myeloid leukemia; pathogenesis; classification; bone marrow dysplasia; HEMATOPOIETIC-CELL TRANSPLANTATION; WORLD-HEALTH-ORGANIZATION; ACUTE MYELOID-LEUKEMIA; LOW-DOSE DECITABINE; SCORING SYSTEM; PROGNOSTIC-FACTORS; OPEN-LABEL; RISK MDS; CLASSIFICATION; SURVIVAL;

D O I：

10.3390/cancers17030508

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Myelodysplastic syndromes (MDSs), either primary or secondary, are a heterogeneous group of clonal hematological neoplasms characterized by bone marrow dyshematopoiesis, peripheral blood cytopenia, and the potential risk of acute myeloid leukemia (AML) transformation. The clinical heterogeneity in MDS is a reflection of the underlying multitude of genetic defects playing a role in the pathogenesis. Recent advances in the clinicopathological, immunophenotypic, and molecular landscape in understanding the pathophysiology of MDS lead to evolving and refined classification systems with newer entities. Evolving MDS therapies will target the disease's core mechanisms, allowing for personalized treatment based on individual patient's genes and leading to better outcomes. This review provides an overview of MDS pathogenesis to enhance comprehension of its various subgroups. Additionally, we examine the updated classification systems of the World Health Organization (WHO) and the International Consensus Classification (ICC) pertaining to MDS, along with relevant therapeutic approaches.

引用

页数：20

共 95 条

[31] Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome [J].

Gerds, Aaron T. ;

Scott, Bart L. ;

Greenberg, Peter ;

Lin, Tara L. ;

Pollyea, Daniel A. ;

Verma, Amit ;

Dail, Monique ;

Feng, Yuning ;

Green, Cherie ;

Ma, Connie ;

Medeiros, Bruno C. ;

Yan, Mark ;

Yousefi, Kasra ;

Donnellan, William .

BLOOD ADVANCES, 2022, 6 (04) :1152-1161

[32] International scoring system for evaluating prognosis in myelodysplastic syndromes [J].

Greenberg, P ;

Cox, C ;

LeBeau, MM ;

Fenaux, P ;

Morel, P ;

Sanz, G ;

Sanz, M ;

Vallespi, T ;

Hamblin, T ;

Oscier, D ;

Ohyashiki, K ;

Toyama, K ;

Aul, C ;

Mufti, G ;

Bennett, J .

BLOOD, 1997, 89 (06) :2079-2088

[33] Revised International Prognostic Scoring System for Myelodysplastic Syndromes [J].

Greenberg, Peter L. ;

Tuechler, Heinz ;

Schanz, Julie ;

Sanz, Guillermo ;

Garcia-Manero, Guillermo ;

Sole, Francesc ;

Bennett, John M. ;

Bowen, David ;

Fenaux, Pierre ;

Dreyfus, Francois ;

Kantarjian, Hagop ;

Kuendgen, Andrea ;

Levis, Alessandro ;

Malcovati, Luca ;

Cazzola, Mario ;

Cermak, Jaroslav ;

Fonatsch, Christa ;

Le Beau, Michelle M. ;

Slovak, Marilyn L. ;

Krieger, Otto ;

Luebbert, Michael ;

Maciejewski, Jaroslaw ;

Magalhaes, Silvia M. M. ;

Miyazaki, Yasushi ;

Pfeilstoecker, Michael ;

Sekeres, Mikkael ;

Sperr, Wolfgang R. ;

Stauder, Reinhard ;

Tauro, Sudhir ;

Valent, Peter ;

Vallespi, Teresa ;

van de Loosdrecht, Arjan A. ;

Germing, Ulrich ;

Haase, Detlef .

BLOOD, 2012, 120 (12) :2454-2465

[34] Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996) [J].

Greenberg, Peter L. ;

Sun, Zhuoxin ;

Miller, Kenneth B. ;

Bennett, John M. ;

Tallman, Martin S. ;

Dewald, Gordon ;

Paietta, Elisabeth ;

van der Jagt, Richard ;

Houston, Jessie ;

Thomas, Mary L. ;

Cella, David ;

Rowe, Jacob M. .

BLOOD, 2009, 114 (12) :2393-2400

[35] Autoimmune manifestations associated with myelodysplastic syndromes [J].

Grignano, Eric ;

Jachiet, Vincent ;

Fenaux, Pierre ;

Ades, Lionel ;

Fain, Olivier ;

Mekinian, Arsene .

ANNALS OF HEMATOLOGY, 2018, 97 (11) :2015-2023

[36] Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide [J].

Gurnari, Carmelo ;

Piciocchi, Alfonso ;

Soddu, Stefano ;

Bonanni, Fabrizio ;

Scalzulli, Emilia ;

Niscola, Pasquale ;

Di Veroli, Ambra ;

Piccioni, Anna Lina ;

Piedimonte, Monica ;

Maiorana, Gianluca ;

Salutari, Prassede ;

Cicconi, Laura ;

Santopietro, Michelina ;

Gumenyuk, Svitlana ;

Sarlo, Chiara ;

Fenu, Susanna ;

Tafuri, Agostino ;

Latagliata, Roberto ;

Fianchi, Luana ;

Criscuolo, Marianna ;

Maciejewski, Jaroslaw P. ;

Maurillo, Luca ;

Buccisano, Francesco ;

Breccia, Massimo ;

Voso, Maria Teresa .

BLOOD CANCER JOURNAL, 2022, 12 (09)

[37] Cytogenetic features in myelodysplastic syndromes [J].

Haase, Detlef .

ANNALS OF HEMATOLOGY, 2008, 87 (07) :515-526

[38] Landscape of genetic lesions in 944 patients with myelodysplastic syndromes [J].

Haferlach, T. ;

Nagata, Y. ;

Grossmann, V. ;

Okuno, Y. ;

Bacher, U. ;

Nagae, G. ;

Schnittger, S. ;

Sanada, M. ;

Kon, A. ;

Alpermann, T. ;

Yoshida, K. ;

Roller, A. ;

Nadarajah, N. ;

Shiraishi, Y. ;

Shiozawa, Y. ;

Chiba, K. ;

Tanaka, H. ;

Koeffler, H. P. ;

Klein, H-U ;

Dugas, M. ;

Aburatani, H. ;

Kohlmann, A. ;

Miyano, S. ;

Haferlach, C. ;

Kern, W. ;

Ogawa, S. .

LEUKEMIA, 2014, 28 (02) :241-247

[39] Risk of Myelodysplastic Syndromes in People Exposed to Ionizing Radiation: A Retrospective Cohort Study of Nagasaki Atomic Bomb Survivors [J].

Iwanaga, Masako ;

Hsu, Wan-Ling ;

Soda, Midori ;

Takasaki, Yumi ;

Tawara, Masayuki ;

Joh, Tatsuro ;

Amenomori, Tatsuhiko ;

Yamamura, Masaomi ;

Yoshida, Yoshiharu ;

Koba, Takashi ;

Miyazaki, Yasushi ;

Matsuo, Tatsuki ;

Preston, Dale L. ;

Suyama, Akihiko ;

Kodama, Kazunori ;

Tomonaga, Masao .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04) :428-434

[40] Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN [J].

Jabbour, Elias ;

Short, Nicholas J. ;

Montalban-Bravo, Guillermo ;

Huang, Xuelin ;

Bueso-Ramos, Carlos ;

Qiao, Wei ;

Yang, Hui ;

Zhao, Chong ;

Kadia, Tapan ;

Borthakur, Gautam ;

Pemmaraju, Naveen ;

Sasaki, Koji ;

Estrov, Zeev ;

Cortes, Jorge ;

Ravandi, Farhad ;

Alvarado, Yesid ;

Komrokji, Rami ;

Sekeres, Mikkael A. ;

Steensma, David P. ;

DeZern, Amy ;

Roboz, Gail ;

Kantarjian, Hagop ;

Garcia-Manero, Guillermo .

BLOOD, 2017, 130 (13) :1514-1522

← 1 2 3 4 5 6 7 8 9 10 →